Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Other Non-Current Liabilities (2021 - 2023)

Historic Other Non-Current Liabilities for Arcturus Therapeutics Holdings (ARCT) over the last 3 years, with Q4 2023 value amounting to $497000.0.

  • Arcturus Therapeutics Holdings' Other Non-Current Liabilities fell 8227.53% to $497000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $497000.0, marking a year-over-year decrease of 8227.53%. This contributed to the annual value of $497000.0 for FY2023, which is 8227.53% down from last year.
  • According to the latest figures from Q4 2023, Arcturus Therapeutics Holdings' Other Non-Current Liabilities is $497000.0, which was down 8227.53% from $976000.0 recorded in Q3 2023.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Other Non-Current Liabilities peaked at $3.7 million during Q3 2022, and registered a low of $358000.0 during Q1 2021.
  • For the 3-year period, Arcturus Therapeutics Holdings' Other Non-Current Liabilities averaged around $1.5 million, with its median value being $1.3 million (2023).
  • Per our database at Business Quant, Arcturus Therapeutics Holdings' Other Non-Current Liabilities skyrocketed by 16370.16% in 2022 and then plummeted by 8227.53% in 2023.
  • Over the past 3 years, Arcturus Therapeutics Holdings' Other Non-Current Liabilities (Quarter) stood at $1.4 million in 2021, then soared by 101.15% to $2.8 million in 2022, then plummeted by 82.28% to $497000.0 in 2023.
  • Its last three reported values are $497000.0 in Q4 2023, $976000.0 for Q3 2023, and $1.3 million during Q2 2023.